# RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

> **NCT06173037** · PHASE2 · COMPLETED · sponsor: **RemeGen Co., Ltd.** · enrollment: 43 (actual)

## Conditions studied

- Primary Peritoneal Cancer
- Fallopian Tube Cancer
- Epithelial Ovarian Cancer

## Interventions

- **DRUG:** RC88

## Key facts

- **NCT ID:** NCT06173037
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-19
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06173037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06173037, "RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06173037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*